Long-term effect of 17β-estradiol and thrombin on tissue factor pathway inhibitor release from HUVEC

Thrombosis Research

Volumn 99, Issue 2, 2000, Pages 173-178

  Bilsel, Ayşe Serpil ^a   Onaran, Nurperi ^a   Moini, Hadi ^a   Emerk, Kaya ^a  

^a MARMARA UNIVERSITY   (Turkey)

Author keywords

17 estradiol; HUVEC; TFPI; Thrombin

Indexed keywords

ESTRADIOL; THROMBIN; TISSUE FACTOR PATHWAY INHIBITOR;

ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; ESTROGEN ACTIVITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN SECRETION;

ANTICOAGULANTS; CELL CULTURE TECHNIQUES; ENDOTHELIUM, VASCULAR; ESTRADIOL; FIBRINOLYTIC AGENTS; HEMOSTATICS; HUMANS; LIPOPROTEINS; THROMBIN; TIME FACTORS; UMBILICAL VEINS;

EID: 0034661198     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(00)00228-0     Document Type: Article

References (33)

1. Vessey M.P., Doll R. Investigation of relation between use of oral contraceptives and thromboembolic disease. Br Med J. 2:1969;651-657.
2. Sartwell P.E., Masi A.T., Arthes F.G., Greene G.R., Smith H.E. Thromboembolism and oral contraceptives. an epidemiological case-control study Am J Epidemiol. 90:1969;365-380.
3. Inman W.H.W., Vessey M.P., Westerholm B., Engelund A. Thromboembolic disease and steroidal content of oral contraceptives. a report to the Committee on Safety of Drugs Br Med J. 2:1970;203-209.
4. Bonnar J. Coagulation effect of oral contraception. Am J Obstet Gynecol. 157:1987;1042-1048.
5. Böttiger L.E., Boman G., Eklund G., Westeholm B. Oral contraceptives and thromboembolic disease. effect of lowering estrogen content Lancet. 1:1980;1097-1101.
6. Daly E., Vessey M.P., Hawkins M.M., Carson J.L., Gough P., Marsh S. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet. 348:1996;977-980.
7. Greer M. Practical strategies for hormone replacement therapy and risk of venous thromboembolism. Br J Obstet Gynocol. 105:1988;376-379.
8. David J.L., Gaspard U.J., Gillian D., Rascinet R., Lepot M.R. Hemostasis profile in women taking low-dose oral contraceptives. Am J Obstet Gynecol. 163:1990;420-423.
9. Meade T.W. Oral contraceptives, clotting factors, and thrombosis. Am J Obstet Gynecol. 142:1982;758-761.
10. Kelleher C.C. Clinical aspect of the relationship between oral contraceptives and abnormalities of the hemostatic system. relation to the development of cardiovascular disease Am J Obstet Gynecol. 163:1990;392-395.
11. Quenherberger P., Loner U., Kapiotis S., Handler S., Schneider B., Huber J., Speiser W. Increased levels of activated factor VII and decreased plasma protein S activity and circulating thrombomodulin during use of oral contraceptives. Thromb Haemost. 76(5):1996;729-734.
12. Koh K.K., Horne M.K., Csako G., Waclawiw M.A., Cannon R.O. Relation of fibrinolytic potential by estrogen to coagulation pathway activation in postmenopausal women. Am J Cardiol. 83:1999;466-469.
13. Caine Y.G., Bauer K.A., Barzegar S., Cate H.T., Sacks F.M., Walsh B.W., Schiff I., Rosenberg R.D. Coagulation activation following estrogen administration to post menopausal women. Thromb Haemost. 68:1992;392-395.
14. Scrabin P.Y., Alhenc-Gelas M., Plu-Bureau G., Taisne P., Agher R., Aiach M. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial. Arterioscler Thromb Vasc Biol. 17:1997;3071-3078.
15. Sandset P.M. Tissue factor pathway inhibitor (TFPI). An update. Haemostasis. 26(Suppl 4):1996;154-165.
16. Rao L.V.M., Rapaport S.I. Studies of a mechanism inhibiting the initiation of the extrinsic pathway of coagulation. Blood. 69:1987;645-651.
17. Broze G.J. Jr., Girard T.J., Novotony W.F. Regulation of coagulation by multivalent Kunitz-type inhibitor. Biochemistry. 29:1990;7539-7546.
18. Sandset P.M., Abildgaard U. Extrinsic pathway inhibitor. the key to feedback control of blood coagulation initiated by tissue thromboplastin Haemostasis. 21:1991;219-239.
19. Sandset P.M., Abildgaard U., Larsen M.L. Heparin induces release of extrinsic coagulation pathway inhibitor (EPI). Thromb Res. 50:1988;803-813.
20. Jaffe E.A. Culture and identification of large vessel endothelial cells. Jaffe E.A. Biology of Endothelial Cells. 1984;1-11 Martinus Nihoff Publisher, Boston.
21. 125I-labeled estradiol and of 3H-R5020. Clin Chem. 27:1981;687-691.
22. Spokes E.G., Wun T.-C. Venous thrombosis produced in the vena cava of rabbits by vascular damage and stasis. JMP. 27:1992;225.
23. Haskel E.J., Torr S.R., Day K.C., Palmier M.O., Wun T.C., Sobel B.E., Abendschein D.R. Prevention of arterial reocclusion after thrombolysis with recombinant lipoprotein associated coagulation inhibitor. Circulation. 84:1991;821-827.
24. Sandset P.M., Warn C.B., Rao L.V., Maki S.L., Rapaport S.I. Depletion of extrinsic pathway inhibitor sentisize rabbits to disseminated intravascular coagulation induced with tissue factor; evidence supporting a physiological role of EPI as a natural anticoagulant. Proc Natl Acad Sci USA. 88:1991;708-712.
25. Sandset P.M., Warn C.B., Maki S.L., Rapaport S.I. Immunodepletion of extrinsic pathway inhibitor sentisizes rabbits to endotoxin-induced intravascular coagulation and generalized Swartzman reaction. Blood. 87:1991;1496-1502.
26. Almus F.E., Rao L.V.M., Rapaport S.I. Regulation of factor VIIa/tissue factor functional activity in an umbilical vein model. Arterioscler Thromb. 13:1992;105-111.
27. Ariens R.S.A., Coppola R., Potenza I., Mannucci P.M. The increase with age of the components of the tissue factor coagulation pathway is gender dependent. Blood Coagul Fibrinolysis. 6:1995;433-437.
28. Evans R. The steroid and thyroid hormone receptor superfamily. Science. 240:1988;889-895.
29. Collins P., Webb C. Estrogen hits the surface. Nature Med. 5:1999;1130-1131.
30. Ferhat M.Y., Abi-Younes S., Ramwell P.W. Non-genomic effects of estrogen and the vessel wall. Biochemical Pharmacol. 51:1996;571-576.
31. Lupu C., Lupu F., Dennehy U., Kakkar V.V., Scully M.F. Thrombin induces the redistribution and acute release of tissue factor pathway-inhibitor from specific granules within human endothelial cells in culture. Arterioscler Thromb Vasc Biol. 15:1995;2055-2062.
32. Woolkalis M.J., DeMelfi T.M., Blanchard N., Hoxie J.A., Brass L.F. Regulation of thrombin receptors on human umbilical vein endothelial cells. J Biol Chem. 270:1995;9868-9875.
33. Okhura N., Enjyoji K., Kamikuba Y., Kato H. A novel degradation pathway of tissue pathway inhibitor. incorporation into fibrin clot and degradation by thrombin Blood. 90:1997;1883-1892.